<DOC>
	<DOCNO>NCT01941836</DOCNO>
	<brief_summary>The purpose research study see ETC-1002 tolerate body , measure amount ETC-1002 blood , determine ETC-1002 affect level LDL-cholesterol ( bad cholesterol ) markers health disease blood urine patient elevate LDL-cholesterol without statin intolerance .</brief_summary>
	<brief_title>Evaluation ETC-1002 , Ezetimibe , Combination Hypercholesterolemic Patients</brief_title>
	<detailed_description>Hypercholesterolemic patient either without history statin intolerance ( 1:1 ratio ) randomize receive daily mouth capsule contain either ETC-1002 , ezetimibe , ETC-1002 + ezetimibe . This study explore safety efficacy concomitant administration ETC-1002 ezetimibe , also explore effect ezetimibe ETC-1002 systemic exposure .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Key Statin intolerant statin tolerant Fasting LDLC 130 mg/dL 220 mg/dL Fasting triglyceride less equal 400 mg/dL Body mass index ( BMI ) 18 45 kg/m2 Key History current clinically significant cardiovascular disease History current type 1 diabetes uncontrolled type 2 diabetes Use metformin thiazolidinediones ( TZD ) within 3 month screen History joint symptom difficult differentiate myalgia Uncontrolled hypothyroidism Liver disease dysfunction Renal dysfunction nephritic syndrome Gastrointestinal ( GI ) condition prior GI procedure HIV AIDS History malignancy History drug alcohol abuse within last 2 year Use experimental investigational drug within 30 day screen Use ETC1002 previous clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Statin intolerant</keyword>
	<keyword>Statin tolerant</keyword>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
</DOC>